Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
NCT00005649
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel and capecitabine in treating women who have metastatic breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
08/15/2017
Locations: PPD Development, Wilmington, North Carolina
Conditions: Breast Cancer
Register for Updates
Local Paclitaxel Delivery for SFA Disease
NCT00821028
Completed
To see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/14/2017
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Atherosclerosis, Angioplasty, Peripheral Arterial Disease
Register for Updates
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
NCT01688609
Completed
This phase II trial studies how well giving lapatinib ditosylate together with trastuzumab, paclitaxel, and surgery works in treating patients with breast cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them.... Read More
Gender:
FEMALE
Ages:
20 years and above
Trial Updated:
08/09/2017
Locations: M D Anderson Cancer Center, Houston, Texas +2 locations
Conditions: HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Register for Updates
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
NCT00004221
Terminated
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/08/2017
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Register for Updates
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
NCT02651727
Terminated
The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose (RP2D) for further development of this combination in subjects with untreated advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2017
Locations: Washington University School of Medicine, Saint Louis, Missouri +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
NCT00466960
Completed
RATIONALE: Colony stimulating factors, such as sargramostim (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing and may also increase the number of immune cells found in bone marrow or peripheral blood and help the immune system recover from the side effects of chemotherapy. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Register for Updates
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00045682
Completed
Phase II trial to study the effectiveness of CT-2103 in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/12/2017
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Register for Updates
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
NCT00003622
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine plus paclitaxel in treating patients with metastatic prostate cancer that is refractory to hormone therapy.
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
07/10/2017
Locations: George Washington University Hospital, Washington, D.C., District of Columbia
Conditions: Prostate Cancer
Register for Updates
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
NCT02651610
Withdrawn
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for HER2-negative metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2017
Locations: Peregrine Pharmaceuticals Investigational Site, Bakersfield, California +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
NCT00183820
Completed
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Gender:
MALE
Ages:
16 years and above
Trial Updated:
07/05/2017
Locations: Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Testicular Cancer, Germ Cell Neoplasm
Register for Updates
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
NCT01911598
Completed
This open-label, multicenter study will evaluate the safety, tolerability, and pharmacokinetics of MEHD7945A in combination with chemotherapy (either cisplatin plus 5-FU or carboplatin plus paclitaxel) in participants with previously untreated R/M SCCHN. There are two stages for each arm in this study: a Dose-limiting Toxicity (DLT)-evaluation stage (Stage I) and a cohort-expansion stage (Stage II). In Stage I, DLTs will be assessed during a DLT Assessment Window of 21 days (i.e., Cycle 1 Day 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2017
Locations: University of Colorado Cancer Center Department of Hematology, Aurora, Colorado +5 locations
Conditions: Head and Neck Cancer
Register for Updates
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
NCT00006110
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy, monoclonal antibody therapy, and surgery may be a more effective treatment for breast cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, monoclonal antibody t... Read More
Gender:
FEMALE
Ages:
Between 1 year and 120 years
Trial Updated:
06/30/2017
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina +1 locations
Conditions: Breast Cancer
Register for Updates